Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265603 · ClinicalTrials.gov registry record · Phase 1
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00265603: Clinical Trial Phase 1 study, sponsored by Atlantic Health System.
NCT00265603 is a Phase 1 study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00265603, a Phase 1 study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization uses a device called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day.
Interventions
- PROCEDURE Extracorporeal Photochemotherapy With Transimmunization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Why NCT00265603 stopped before completion
NCT00265603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Extracorporeal Photochemotherapy With Transimmunization is the first listed.
NCT00265603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00265603 about?
NCT00265603 is a clinical study titled "Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer". The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization u...
What is the current status of trial NCT00265603?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2004-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00265603?
The interventions under investigation include: Extracorporeal Photochemotherapy With Transimmunization (PROCEDURE).
Who is sponsoring clinical trial NCT00265603?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00265603's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia